Trial Profile

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Subjects With Sickle Cell Disease

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tebapivat (Primary)
Indications Sickle cell anaemia
Focus Adverse reactions; First in man
Sponsors Agios Pharmaceuticals

Most Recent Events

05 Nov 2024 According to an Agios Pharmaceuticals media release,data of this trial will be featured in oral and poster presentations during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California from December 7-10, 2024
19 Jan 2024 Status changed from active, no longer recruiting to completed.
13 Nov 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com